Promising new combo tackles rare blood cancer
Disease control
Not yet recruiting
This study tests a new three-drug combination (sintilimab, chidamide, and azacitidine) as the first treatment for people with early-stage extranodal NK/T-cell lymphoma, a rare blood cancer. About 30 participants will receive the drugs, and depending on how well the cancer respond…
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC